IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
Com pe ti tion: In the year end ing Sep tem ber 2008, Gasmotin was the world’s lead ing Gastroprokinetic
ac cord ing to IMS with 13.7% of global sales, up 5% over the pre vi ous year. John son & John son/Kyowa
Hakko’s Motilium (domperidone) was in sec ond place with 13.3% (down 1%) fol lowed by
Pfizer/Mitsubishi Tanabe Pharma’s Debridat (trimebutine) with 5.9% (down 11%).
GLUFAST (mitiglinide), an antidiabetic po tas sium chan nel in hib i tor de signed to sup press post-pran dial
hyperglycemia. In May 2004, Kissei and li censee Takeda launched Glufast in Ja pan for the treat ment of
Type 2 diabetes.
Li cens ing: Mitiglinide was li censed-in from Kissei in 2002 for co-mar ket ing in Ja pan.
Lifecycle Man age ment: The com pound was filed for ap proval in Ja pan in April 2007 as a con com i tant
ther apy with an in su lin sensitizer.
Com pe ti tion: In the year end ing Sep tem ber 2008, Glufast was Ja pan’s sixth lead ing oral antidiabetic
with 4.3% of do mes tic sales, and growth of 23%. Takeda’s Basen (voglibose) was Ja pan’s lead ing oral
di a betic ac cord ing to IMS with 28% share of do mes tic sales, down 6% (fixed dol lar rate) over the pre vi -
ous year. Takeda’s Actos (pioglitazone) took sec ond place with 25.1% and 22% growth while Amaryl
(glimepiride) took third place with 13.3% (up 10%). Glufast also com petes with Astellas’ (Ja pan) Starsis
(nateglinide), which is also mar keted by Daiichi Sankyo (Ja pan) un der the name of Fastic, which ranked
just be hind Glufast with Fastic in sev enth place hold ing 2.9% mar ket share (down 1%) and Starsis in
eighth po si tion with 2.4% mar ket share (up 1%). There is a cer tain amount of pos i tive in ter play be tween
the prod ucts in that Glufast will help heighten aware ness of short and fast-act ing in su lin sectretagogues,
ac cord ing Astellas. There is also syn ergy with Takeda’s established brands like Basen and Actos.
Sales/An a lyst Com ment: With sales of Yen3.2 bil lion in fis cal 2007 (end ing March 2008) an a lysts at
Mor gan Stan ley (Au gust 2008) fore cast sales of Yen12 bil lion by the year end ing March 2013.
LANSAP/PREVPAC (lansoprazole + amoxicillin + clarithromycin) is a sin gle tri ple ther apy pack de -
signed for the erad i ca tion of H. pylori. The prod uct, de signed to im prove com pli ance, com prises in di vid ual
packs con tain ing all the med i ca tion with lansoprazole, Abbott’s Biaxin (clarithromycin) and amoxicillin,
re quired for a sin gle day. In the USA, TAP mar kets the tri ple ther apy as Prevpac, and the com bi na tion
has also been launched in a num ber of other mar kets, in clud ing the UK and France. In 1999, Takeda,
Taisho (Ja pan) and Dainabot, Abbott’s Jap a nese jv with Dainippon (Ja pan), filed the reg i men in Ja pan,
and it was launched in 2002 in Japan.
Sales/An a lyst Com ment: In the year end ing Sep tem ber 2008, Prevpac be came Takeda’s 10th lead ing
in ter na tional prod uct ac cord ing to IMS with 1% mar ket share down 1% (fixed dol lar growth rate).
TAKEPRON/PREVACID/OGASTRO (lansoprazole), a sub sti tuted benzimidazole pro ton pump in hib i -
tor with po tent and long-last ing antisecretory ac tiv ity, was pat ented and de vel oped by Takeda, and was
launched in Ja pan in 1992. It was first launched in France in 1991, and is now avail able in most coun tries
world wide via Takeda and a num ber of li cens ees. Lansoprazole is used and ap proved for a va ri ety of in di -
ca tions in a num ber of coun tries, in clud ing gastroesophageal re flux dis ease (GERD), pep tic ul cers,
NSAID-as so ci ated gas tric ul cers (phase III tri als on go ing in Ja pan in 2008), acid-re lated dys pep sia,
Zollinger-Ellison syn drome, main te nance ther apy af ter ul cer heal ing, and main te nance ther apy for
GERD. In De cem ber 2006, Takeda launched an in tra ve nous for mu la tion of lansoprazole (Takepron iv) for
the treat ment of bleed ing as so ci ated with gastrointestinal ulcers in patients unable to take the drug
orally.
Prevacid of fers a va ri ety of ad min is tra tion modes: an oral sus pen sion form and an orally dis in te grat ing
tab let. Prevacid SoluTab is a for mu la tion which dis in te grates quickly in the mouth, usu ally less than 60
sec onds, and can be taken with or with out wa ter. In 2004 the FDA has ap proved this for mu la tion of
lansoprazole to be given us ing an oral sy ringe or nasogastric tube. An orally dis in te grat ing tab let,
© 2009 IMS Health In cor po rated or its af fil i ates Page 30